CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Volastra reports promising Phase 1/2 data for VLS-1488 in solid tumors, with good safety and early efficacy signals in ...

Plus, news about Sanofi, Servier, BioNova, Arcutis, Roche, Satellos Bioscience, Fore Biotherapeutics, Cinclus Pharma and Zentiva.

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

The House of Representatives on Thursday passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

The White House released its first MAHA Commission report, detailing some of the Trump administration’s top priorities for ...

After a median 34.2 months of follow-up, patients taking Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex survived for a median of 34 months, compared to 27 months for those ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...